12:45 PM EST, 11/18/2024 (MT Newswires) -- Cardiol Therapeutics ( CRDL ) developing therapies for the treatment of heart disease, on Monday reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis.

The data showed that the marked improvements in both pericarditis pain and inflammation, previously reported at the eight-week primary endpoint, were maintained throughout the extension period of the 26-week study. The data were included in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture at the American Heart Association Scientific Sessions 2024.

The study enrolled 27 participants at eight clinical sites in the United States. Cardiol said the findings support a Phase III trial to assess CardiolRx for the treatment of pericarditis patients to prevent recurrence.

"The data reported today show that patients enrolled in MAvERIC-Pilot, despite the severity of their disease, experienced clinically relevant and rapid reductions in both their pericarditis pain and C-reactive protein levels that were maintained throughout the study. In addition, results demonstrated a substantial reduction in pericarditis episodes per year as compared to the patients' historical event rate prior to the study. Importantly, treatment was shown to be safe and well tolerated in a population who presented with significant disease burden," said study presenter Dr. S. Allen Luis, from the Mayo Clinic.

Cardiol shares were last seen down $0.05 to $2.49 on the Toronto Stock Exchange.

Price: 2.48, Change: -0.06, Percent Change: -2.36